Article

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

Center for Cellular and Molecular Medicine, Kyushu University Graduate School of Medical Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
International journal of hematology (Impact Factor: 1.68). 07/2009; 90(2):253-60. DOI: 10.1007/s12185-009-0370-x
Source: PubMed

ABSTRACT We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m(2) rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.

0 Followers
 · 
110 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic stem cell transplantation is an established treatment modality for malignant and nonmalignant hematologic diseases. Acute and chronic graft-versus-host diseases (GVHDs) are a major cause of morbidity and mortality after allogeneic stem cell transplantation. T cells have been identified as key players in the graft-versus-host reaction and, therefore, most established drugs used against GVHD target T cells. Despite our knowledge on the pathogenesis of the GVH reaction, success of established therapies for prevention and treatment of GHVD is unsatisfactory. Recently, animal and human studies demonstrated that B cells are involved in the immunopathophysiology of acute and chronic GVHD. Early phase clinical trials of B-cell depletion with rituximab have shown beneficial effects on both acute and chronic GVHD. This review summarizes the current experimental and clinical evidence for the involvement of B cells in the pathogenesis of acute and chronic GVHD and discusses the clinical implications for the management of patients undergoing allogeneic stem cell transplantation.
    Blood 09/2009; 114(24):4919-27. DOI:10.1182/blood-2008-10-161638 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rituximab (RTX) has been successfully used in the treatment of several rheumatic diseases with an acceptable safety profile. We present herein a patient with systemic sclerosis (SSc) who exhibited significant improvement of his lung function and skin fibrosis following RTX administration, and review the literature regarding the role of B-cells in SSc and the potential efficacy of RTX in its treatment. We performed an internet search using the keywords systemic sclerosis, scleroderma, rituximab, B-cells, fibrosis, interstitial lung disease (ILD), and therapy. Our patient, a 40-year old man with severe SSc-associated ILD, received 4 courses of RTX. The patient's lung function improved; forced vital capacity and diffusing capacity of carbon monoxide reached values of 35% and 33%, respectively, compared with 30% and 14% of pretreatment values. Skin thickening assessed clinically and histologically improved as well. Several lines of evidence suggest that B-cells may have a pathogenic role in SSc. B-cells from tight skin mice--an animal model of SSc--exhibit chronic hyperactivity; likewise, B-cells from patients with SSc overexpress CD19 and are chronically activated. Furthermore, studies have revealed that B-cell genes were specifically transcribed in SSc skin and that B-cell infiltration was a prominent feature of SSc-associated ILD. The potential clinical efficacy of RTX in SSc has been explored in a limited number of patients with encouraging results. Preliminary data suggest that RTX may favorably affect skin as well as lung disease in SSc. Several basic research data underscore the potential pathogenic role of B-cells in SSc and clinical evidence suggests that RTX might be a therapeutic option in SSc. Large-scale multicenter studies are needed to evaluate the potential clinical efficacy of RTX in SSc.
    Seminars in arthritis and rheumatism 12/2009; 40(2):127-36. DOI:10.1016/j.semarthrit.2009.09.003 · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Graft versus host disease (GVHD) remains a common complication following allogeneic hematopoietic cell transplant (HCT). Historically, research into prevention and treatment of GVHD has centered on donor T lymphocytes using strategies to suppress or deplete these cells. The role of B lymphocytes in the pathogenesis of this disease was brought to prominence following a case report of a patient with chronic GVHD who responded to B cell depletion therapy with rituximab. Since this original observation, several clinical trials and case series have been published on the use of B cell depletion using rituximab in the treatment of chronic GVHD. Corresponding to this clinical experience, considerable laboratory evidence has revealed the complex interactions between B and T cells which culminate in acute and chronic GVHD. More recently, researchers have examined the link between B cell immune reconstitution following HCT and the development of chronic GVHD. The focus of the next decade will likely be on prevention and treatment of GVHD through targeted therapies directed at key pathways in this process. This article provides an overview of the current understanding regarding the role of B cells in GVHD along with discussion on how this knowledge will be used to direct future therapies.
    Leukemia & lymphoma 02/2010; 51(3):376-89. DOI:10.3109/10428190903586318 · 2.61 Impact Factor